187 related articles for article (PubMed ID: 20711577)
1. ¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.
Groves AM; Shastry M; Rodriguez-Justo M; Malhotra A; Endozo R; Davidson T; Kelleher T; Miles KA; Ell PJ; Keshtgar MR
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):46-52. PubMed ID: 20711577
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.
Cochet A; Pigeonnat S; Khoury B; Vrigneaud JM; Touzery C; Berriolo-Riedinger A; Dygai-Cochet I; Toubeau M; Humbert O; Coudert B; Fumoleau P; Arnould L; Brunotte F
J Nucl Med; 2012 Apr; 53(4):512-20. PubMed ID: 22343501
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Shigekawa T; Fukatsu K; Kondo N; Yamamoto M; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
Jpn J Clin Oncol; 2008 Apr; 38(4):250-8. PubMed ID: 18407934
[TBL] [Abstract][Full Text] [Related]
4. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.
Groheux D; Giacchetti S; Moretti JL; Porcher R; Espié M; Lehmann-Che J; de Roquancourt A; Hamy AS; Cuvier C; Vercellino L; Hindié E
Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):426-35. PubMed ID: 21057787
[TBL] [Abstract][Full Text] [Related]
5. Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT.
Groves AM; Wishart GC; Shastry M; Moyle P; Iddles S; Britton P; Gaskarth M; Warren RM; Ell PJ; Miles KA
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):416-21. PubMed ID: 18818917
[TBL] [Abstract][Full Text] [Related]
6. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
8. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors.
Kaira K; Okumura T; Ohde Y; Takahashi T; Murakami H; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
J Nucl Med; 2011 May; 52(5):705-11. PubMed ID: 21498541
[TBL] [Abstract][Full Text] [Related]
9. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study.
Schinagl DA; Span PN; Oyen WJ; Kaanders JH
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1449-58. PubMed ID: 21461734
[TBL] [Abstract][Full Text] [Related]
10. Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma.
Kaira K; Endo M; Abe M; Nakagawa K; Ohde Y; Okumura T; Takahashi T; Murakami H; Tsuya A; Nakamura Y; Naito T; Hayashi I; Kondo H; Nakajima T; Yamamoto N
Lung Cancer; 2011 Feb; 71(2):144-50. PubMed ID: 20646779
[TBL] [Abstract][Full Text] [Related]
11. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma.
Ekmekcioglu O; Aliyev A; Yilmaz S; Arslan E; Kaya R; Kocael P; Erkan ME; Halac M; Sonmezoglu K
Nucl Med Commun; 2013 Nov; 34(11):1055-67. PubMed ID: 24025919
[TBL] [Abstract][Full Text] [Related]
12. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
14. Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors.
García Vicente AM; Soriano Castrejón A; Cruz Mora MA; González Ageitos A; Muñoz Sánchez Mdel M; León Martín A; Espinosa Aunión R; Relea Calatayud F; Muñoz Madero V; Chacón López-Muñiz I; Cordero García JM; Jiménez Londoño GA
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):72-9. PubMed ID: 23053321
[TBL] [Abstract][Full Text] [Related]
15. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
18. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
Connolly RM; Leal JP; Goetz MP; Zhang Z; Zhou XC; Jacobs LK; Mhlanga J; O JH; Carpenter J; Storniolo AM; Watkins S; Fetting JH; Miller RS; Sideras K; Jeter SC; Walsh B; Powers P; Zorzi J; Boughey JC; Davidson NE; Carey LA; Wolff AC; Khouri N; Gabrielson E; Wahl RL; Stearns V
J Nucl Med; 2015 Jan; 56(1):31-7. PubMed ID: 25476537
[TBL] [Abstract][Full Text] [Related]
19. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
20. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Vrancken Peeters MJ; Wesseling J; Lips EH; Vogel WV; Aukema TS; van Werkhoven E; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1830-8. PubMed ID: 22895862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
